改良ROX指数预测SARS-CoV-2感染相关ARDS患者经鼻高流量氧疗结局的价值
该回顾性观察研究纳入2022年12月至2023年6月兰州大学第二医院ICU收治的57例SARS-CoV-2感染相关ARDS需HFNC治疗的患者,按是否成功脱离HFNC分为成功组(34例)与失败组(23例)。失败组降钙素原、C反应蛋白、白细胞介素-6、乳酸、血管活性药物比例、CRRT比例、APACHE II评分、SOFA评分及治疗即刻和6小时呼吸频率均显著高于成功组,氧合指数及治疗即刻和6小时SpO2、PaO2、ROX指数、mROX指数均显著低于成功组(均P<0.05)。多因素Logistic回归显示乳酸、SOFA评分、6小时ROX指数、6小时mROX指数与HFNC治疗结局相关(均P<0.05)。ROC曲线显示6小时mROX指数预测HFNC成功的AUC为0.809,高于6小时ROX指数的0.714(P<0.01), cut-off值4.5时敏感度88.2%、特异度52.2%。
要点
- SARS-CoV-2感染相关ARDS行HFNC者,治疗6小时mROX指数>4.5更可能预测HFNC治疗成功(敏感度88.2%、特异度52.2%)。
- 6小时mROX指数预测HFNC成功的AUC为0.809,显著高于6小时ROX指数的0.714(P<0.01)。
- HFNC失败组28天累积生存率26.1%、90天累积生存率21.7%,均显著低于成功组的100%和85.3%(均P<0.001)。
- 多因素Logistic回归中,乳酸(OR=0.129,95%CI 0.020-0.824)、SOFA评分(OR=0.382,95%CI 0.158-0.925)、6小时ROX指数(OR=0.099,95%CI 0.011-0.920)、6小时mROX指数(OR=23.703,95%CI 1.415-396.947)与HFNC治疗结局相关(均P<0.05)。
- HFNC失败组降钙素原、C反应蛋白、白细胞介素-6、乳酸、血管活性药物比例、CRRT比例、APACHE II评分、SOFA评分及治疗即刻和6小时呼吸频率均显著高于成功组,氧合指数及治疗即刻和6小时SpO2、PaO2、ROX指数、mROX指数均显著低于成功组(均P<0.05)。
适用人群与场景
- 2022年12月至2023年6月兰州大学第二医院ICU收治的SARS-CoV-2感染相关ARDS需HFNC治疗的患者57例。
- 按是否成功脱离HFNC分为HFNC成功组(34例)与HFNC失败组(23例)。
诊断标准与关键阈值
- 6小时mROX指数 cut-off值为4.5时,预测HFNC治疗成功的敏感度为88.2%、特异度为52.2%。
- 6小时mROX指数预测HFNC成功的AUC为0.809,6小时ROX指数为0.714。
研究设计与关键结果
- 回顾性观察研究,纳入57例SARS-CoV-2感染相关ARDS接受HFNC治疗的患者,HFNC成功组34例、失败组23例。
- HFNC失败组降钙素原、C反应蛋白、白细胞介素-6、乳酸、血管活性药物比例、CRRT比例、APACHE II评分、SOFA评分及治疗即刻和6小时呼吸频率均显著高于成功组(均P<0.05)。
- HFNC失败组氧合指数及治疗即刻和6小时SpO2、PaO2、ROX指数、mROX指数均显著低于成功组(均P<0.05)。
- Kaplan-Meier生存曲线显示,HFNC成功组28天累积生存率100%、90天累积生存率85.3%,均显著高于失败组的26.1%和21.7%(均P<0.001)。
- 多因素Logistic回归显示,乳酸(OR=0.129,95%CI 0.020-0.824)、SOFA评分(OR=0.382,95%CI 0.158-0.925)、6小时ROX指数(OR=0.099,95%CI 0.011-0.920)、6小时mROX指数(OR=23.703,95%CI 1.415-396.947)与HFNC治疗结局相关(均P<0.05)。
- ROC曲线显示,6小时mROX指数预测HFNC成功的AUC为0.809,6小时ROX指数为0.714,6小时mROX指数AUC显著高于6小时ROX指数(P<0.01);6小时mROX指数 cut-off值4.5时敏感度88.2%、特异度52.2%。
证据类型、等级与局限
- 回顾性观察研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,6小时mROX指数对SARS-CoV-2感染相关ARDS患者HFNC治疗的预测价值高于6小时ROX指数,6小时mROX指数大于4.5更可能预测HFNC治疗成功。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the value of the modified ROX (mROX) index in predicting the outcome of patients with acute respiratory distress syndrome (ARDS) due to SARS-CoV-2 infection treated with high-flow nasal cannula oxygen therapy (HFNC).
METHODS: A retrospective observational study was conducted, including 57 patients with ARDS caused by SARS-CoV-2 infection who required HFNC treatment in the intensive care unit (ICU) of the Lanzhou University Second Hospital from December 2022 to June 2023. The patients were divided into HFNC failure group and HFNC success group according to whether they were successfully weaned from HFNC. Laboratory tests, acute physiology and chronic health evaluation II (APACHE II), and sequential organ failure assessment (SOFA) in the first 24 hours of ICU admission were recorded in both groups, vital signs and arterial blood gas analysis immediately and after 6 hours of HFNC treatment, treatment regimen, length of ICU stay, and total length of hospital stay were recorded in both groups, and patients' outcomes at 28 days and 90 days were followed up by telephone. Univariate analysis was used to analyze the above indexes, and the significant indexes were included in the binary multivariate Logistic regression analysis to analyze the influencing factors of HFNC failure in patients. Kaplan-Meier survival curves were plotted to analyze the 28-day and 90-day outcomes of patients in both groups. Receiver operator characteristic curve (ROC curve) was plotted to analyze the value of treatment 6-hour mROX index and 6-hour ROX index in predicting the success of HFNC.
RESULTS: A total of 57 patients with ARDS due to SARS-CoV-2 infection were enrolled, including 34 patients in the HFNC success group and 23 patients in the HFNC failure group. Procalcitonin (PCT), C-reactive protein (CRP), interleukin-6 (IL-6), lactic acid (Lac) and the proportion of vasopressors, the proportion of continuous renal replacement therapy (CRRT), the APACHE II score and the SOFA score, the respiratory rate (RR) immediately and 6 hours after treatment were significantly higher in the HFNC failure group compared with the HFNC success group. The length of ICU stay was significantly longer, and oxygenation index (PaO2/FiO2) at the time of treatment, and pulse oxygen saturation (SpO2), arterial partial pressure of oxygen (PaO2), ROX index, and mROX index at the time of treatment and at 6 hours after treatment were significantly lower in the HFNC failure group compared with the HFNC success group (all P < 0.05). Kaplan-Meier survival curves showed that the 28-day cumulative survival rates (100% vs. 26.1%) and 90-day cumulative survival rates (85.3% vs. 21.7%) of patients in the HFNC success group were significantly higher than those in the HFNC failure group (both P < 0.001). On binary multivariate Logistic regression analysis, Lac [odds ratio (OR) = 0.129, 95% confidence interval (95%CI) was 0.020-0.824], SOFA score (OR = 0.382, 95%CI was 0.158-0.925), 6-hour ROX index (OR = 0.099, 95%CI was 0.011-0.920), and 6-hour mROX index (OR = 23.703, 95%CI was 1.415-396.947) were associated with HFNC treatment outcome (all P < 0.05). ROC curve analysis showed that the area under the ROC curve (AUC) of the 6-hour mROX index and the 6-hour ROX index for predicting the success of HFNC were both higher (0.809 and 0.714, respectively), and the AUC of 6-hour mROX index was significantly higher than that of 6-hour ROX index (P < 0.01), and the sensitivity was 88.2% and the specificity was 52.2% when the cut-off value of 6-hour mROX index was 4.5.
CONCLUSIONS: The predictive value of the 6-hour mROX index in the treatment of patients with ARDS caused by SARS-CoV-2 infection is higher than that of the 6-hour ROX index, and the 6-hour mROX index is greater than 4.5, which is more likely to predict the success of HFNC treatment.
参考来源
- Wang X, Zhang Z, Cao W, et al. [Value of modified ROX index in predicting the outcome of patients with acute respiratory distress syndrome due to SARS-CoV-2 infection treated with high-flow nasal cannula oxygen therapy]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2024. PMID: 38991956. doi:10.3760/cma.j.cn121430-20240228-00171
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。